Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· January 12, 2026

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

View original at globenewswire.com

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight New York, USA, Jan…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

In 2024, the total diagnosed prevalent cases of ASCVD across the 7MM were approximately 65 million, and this burden is projected to rise over the forecast period
80% confidence
While marketed therapies have cemented PCSK9 inhibition as a powerful intervention, uptake challenges have left room for innovation. This gap is now fueling a new wave of competition with oral, long-acting, and gene-editing approaches.
80% confidence
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025-2034) at a CAGR of 4.9%
80% confidence
In the United States, systemic inflammation-associated ASCVD cases were estimated at approximately 17 million in 2024
80% confidence
The ASCVD clinical trial landscape is undergoing a notable transition, moving beyond traditional LDL-C-focused strategies toward more targeted, mechanism-based interventions for cardiovascular risk reduction
80% confidence
The market size for atherosclerotic cardiovascular disease was USD 23 billion in the leading markets in 2024
80% confidence
Despite strong clinical validation, real-world adoption challenges for existing PCSK9 inhibitors have opened the door to next-generation therapies
80% confidence
The dynamics of the ASCVD market are expected to change in the coming years due to the launch of emerging therapies
80% confidence
The advancement of late-stage candidates such as Amgen's olpasiran and Ionis/Novartis' pelacarsen highlights the increasing clinical and commercial emphasis on lipoprotein(a), a genetically determined and long-overlooked contributor to residual ASCVD risk
80% confidence
The United States accounted for approximately 75% of the total ASCVD market size in the 7MM in 2024
80% confidence